Products for Out-Licensing

Products Out-Licensing

NAL develops novel dosage forms and proprietary drug delivery systems based on Company’s captive Drug Delivery System (“DDS”) technologies. NAL expects to partner with pharmaceutical companies for the development and commercialization of the NAL products in global markets.

The partial listing of NAL’s products is outlined below. As we have not disclosed the complete list of our proprietary DDS products under development, please write to us at to know more about NAL’s products and partnering opportunities.

Urology, Metabolic and Cardiovascular Disease
Products Marketed or Under Development (Partial Listing)
Proposed US Filing
NAL8233 Tadalafil ODF for Erectile Dysfunction
505(b)(2) NDA
NAL8238 Sildenafil ODF for Erectile Dysfunction
505(b)(2) NDA
NAL8256 Ambrisentan Tablet for Pulmonary Arterial Hypertension (PAH)
NAL8212 Rivaroxaban Tablet for Thrombosis
NAL3923 Exenatide Microsphere Injection for Diabetes Type 2